



(51) International Patent Classification:

C07K 1/18 (2006.01) C07K 16/00 (2006.01)
C07K 1/36 (2006.01)

(21) International Application Number:

PCT/US2024/019487

(22) International Filing Date:

12 March 2024 (12.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/490,079 14 March 2023 (14.03.2023) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **BASCONI, Joseph Edward**; c/o Amgen Inc., Law Department-Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **MALONEY, Andrew John**; c/o Amgen Inc., Law Department-Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **VECCHIARELLO, Nicholas Anthony**; c/o Amgen Inc., Law Department-Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799

(US). **NAMBIAR, Arun Kannoth**; c/o Amgen Inc., Law Department-Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **BOLTON, Glen**; c/o Amgen Inc., Law Department-Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) Agent: **MADL, Amy**; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: ANION EXCHANGE CHROMATOGRAPHY PROCESSES USING A PRIMARY AMINE LIGAND

High Molecular Weight Clearance for mAb1




FIG. 1A

(57) Abstract: Disclosed herein are methods for purifying a recombinant protein from a composition comprising the recombinant protein and at least one impurity, the methods comprising performing anion exchange chromatography (e.g., in flow-through or weak partitioning chromatography mode) using an anion exchange material comprising a primary amine ligand, such as a polyamine ligand.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*